You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
冠昊生物(300238.SZ):擬與美國參股公司開展新型肺炎冠狀病毒mRNA疫苗(Z-VacciRNA)的研究和臨牀項目
格隆匯 02-03 13:07

格隆匯2月3日丨冠昊生物(300238.SZ)公佈,鑑於突如其來的新型冠狀病毒及目前嚴峻的疫情形勢,醫藥企業應積極思考如何發揮自身技術優勢,為國家與社會作出應有的貢獻。公司作為甲方與參股公司ZY公司作為乙方於2020年2月2日簽訂了《核酸疫苗項目合作意向框架協議》,甲、乙雙方經友好協商,同意由甲方以投資首期研發款、乙方負責研發的方式開展標的項目:“ZY核酸疫苗項目”,擬開展新型肺炎冠狀病毒mRNA疫苗(Z-VacciRNA)的研究和臨牀項目,項目研發費用總額預估300萬美元。

該項目計劃針對已經公開的新型冠狀病毒基因組序列,篩選出數條可有特異性的病毒蛋白mRNA候選藥物;然後利用ZY的藥物傳輸技術將這些候選mRNA藥物做成凍乾粉針劑,通過體外和體內實驗確定1-2個候選藥物後,由ZY做成製劑開展臨牀前毒性研究,最後在中國申報藥監管理部門開展臨牀實驗,並最終在中國生產和銷售。

據悉,ZY公司於2015年9月15日設立,是一家生物醫藥技術公司,公司註冊地位於美國北卡羅萊納州。主營業務是開發並市場化創新的納米靶向藥物傳送平台、創新型紫杉醇多糖載體腫瘤新藥(ZY-010)、紫杉醇白蛋白結合型改良針劑(ZY-020)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account